Spruce Biosciences, Inc. Common Stock

SPRB.US
Healthcare · Biotechnology
41.60
-0.39 (-0.93%)
USD · NASDAQ

Company Information

▼
Company Name
Spruce Biosciences, Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US85209E1091
CIK: 0001683553
CUSIP: 85209E109
Currency: USD
Full Time Employees: 14
Phone: 415 343 5986
Website: https://sprucebio.com
Fiscal Year End: December
IPO Date: Oct 09, 2020
Description:

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Address:

611 Gateway Boulevard, South San Francisco, CA, United States, 94080

People

▼

Directors & Officers

Name Title Year Born
Mr. Michael G. Grey Executive Chairman 1953
Dr. Javier Szwarcberg M.D., M.P.H. CEO & Director 1970
Mr. Samir M. Gharib CPA, M.B.A. President & CFO 1982
Dr. Kirk Ways M.D., Ph.D. Chief Medical Officer & Director 1953
Mr. Bruno Gagnon BPHARM, M.Sc. Senior Vice President of Clinical Development Operations 1969
Dr. Daven Mody Pharm.D. Senior Vice President of Regulatory & Quality NA
Mr. Corwin Dale Hooks Chief Commercial Officer 1967

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 06, 2025 Parkman Healthcare Partners Ll N/A Purchase 256.00 $17.91 $4.58K
Oct 06, 2025 Parkman Healthcare Partners Ll N/A Sale 257.00 $19.14 $4.92K

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Ikarian Capital, LLC 121.36K Mar 31, 2026 4.41% $0.64 0.00%
Millennium Management LLC 111.89K Mar 31, 2026 4.07% $0.00 0.00%
Citadel Advisors Llc 70.00K Mar 31, 2026 2.54% $0.00 0.00%
ADAR1 Capital Management LLC 58.60K Mar 31, 2026 2.13% $0.23 1.03%
Alyeska Investment Group, L.P. 51.67K Mar 31, 2026 1.88% $0.01 0.00%
Wellington Management Company LLP 48.80K Mar 31, 2026 1.77% $0.00 -17.22%
BOOTHBAY FUND MANAGEMENT, LLC 42.08K Mar 31, 2026 1.53% $0.04 -12.21%
Balyasny Asset Management LLC 40.00K Mar 31, 2026 1.45% $0.00 0.00%
The Carlyle Group Inc 38.62K Mar 31, 2026 1.40% $0.02 0.00%
Quinn Opportunity Partners LLC 26.81K Mar 31, 2026 0.97% $0.09 17.54%
ExodusPoint Capital Management, LP 22.00K Mar 31, 2026 0.80% $0.01 -12.94%
Vanguard Capital Management, LLC 18.34K Mar 31, 2026 0.67% $0.00 0.00%
Vanguard Group Inc 17.87K Dec 31, 2025 0.65% $0.00 0.00%
BlackRock Inc 16.94K Mar 31, 2026 0.62% $0.00 0.00%
Geode Capital Management, LLC 12.89K Mar 31, 2026 0.47% $0.00 1.23%
StemPoint Capital LP 12.72K Mar 31, 2026 0.46% $0.08 0.00%
Squadron Capital Management LLC 12.20K Mar 31, 2026 0.44% $0.29 -82.57%
Diadema Partners LP 10.00K Mar 31, 2026 0.36% $0.11 0.00%
Vanguard Fiduciary Trust Co 5.51K Mar 31, 2026 0.20% $0.00 0.00%
The Goldman Sachs Group Inc 5.51K Mar 31, 2026 0.20% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 84.94K 3.09% ▲ 11.41% Jun 30, 2026
2 iShares Russell 2000 ETF 67.34K 2.45% ▲ 3.25% Jun 30, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 31.89K 1.16% ▲ 168.81% Jun 30, 2026
4 Russell 2000 Equity Index Fund B 17.40K 0.63% ▲ 0.00% Jun 30, 2026
5 Russell 2000 Index Non-Lendable Fund 17.40K 0.63% ▲ 0.00% Jun 30, 2026
6 iShares Russell 2000 Value ETF 17.18K 0.62% ▲ 1.86% Jun 30, 2026
7 State St Russell Sm/Mid Cp® Indx SL Cl I 15.90K 0.58% ▲ 0.00% Jun 30, 2026
8 Vanguard Russell 2000 ETF 15.70K 0.57% ▲ 0.00% Jun 30, 2026
9 State St Russell Sm Cap® Idx SL Cl I 10.10K 0.37% ▲ 0.00% Jun 30, 2026
10 iShares Micro-Cap ETF 8.89K 0.32% ▲ 2.62% Jun 30, 2026

Financial Highlights

▼
Market Cap: $115.57M
EBITDA: $-25.84M
Book Value: $25.25
Earnings/Share: $-34.94
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -37.16%
ROE (TTM): -148.85%
Revenue (TTM): $697.00K
Revenue/Share (TTM): $1.20
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -75.90%

Valuation Metrics

Enterprise Value: $71.61M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 2.75M
Shares Float: 2.65M
% Insiders: 352.30%
% Institutions: 3,214.30%
Short % Float: 15.27%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-21.00K
Gross Profit
subtotal
$-21.00K
SG&A
adjust
$-16.99M
R&D
adjust
$-19.52M
Operating Income
subtotal
$-36.51M
Other / Non-Operating Items
adjust
$-2.45M
Net Income
subtotal
$-38.97M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SPRB.US!